Anticipated Pain During Intrauterine Device Insertion - 17/01/20
, Sarita Sonalkar, MD, MPH 2, Courtney A. Schreiber, MD, MPH 2, Lisa K. Perriera, MD, MPH 3, Mary D. Sammel, ScD 4, Aletha Y. Akers, MD 5Abstract |
Study Objective |
To identify predictors of anticipated pain with intrauterine device (IUD) insertion in adolescents and young women.
Design |
We performed linear regression to identify demographic, sexual/gynecologic history, and mood covariates associated with anticipated pain using a visual analogue scale pain score collected as part of a single-blind randomized trial of women who received a 13.5-mg levonorgestrel IUD.
Setting |
Three academic family planning clinics in Philadelphia Pennsylvania.
Participants |
Ninety-three adolescents and young adult women aged 14-22 years.
Intervention |
Participants received either a 1% lidocaine or sham paracervical block.
Main Outcome Measures |
Anticipated pain measured using a visual analogue scale before and perceived pain at 6 time points during the IUD insertion procedure.
Results |
Black or African American participants had a median anticipated pain score of 68 (interquartile range [IQR], 52-83), White participants had a median anticipated pain of 51 (IQR, 35-68), whereas participants of other races had a median anticipated pain score of 64 (IQR, 36-73); P = .012. In multivariate analysis, race was the only covariate that significantly predicted anticipated pain at IUD insertion. Women with anticipated pain scores above the median had significantly higher perceived pain during all timepoints of the IUD insertion procedure.
Conclusion |
Increased anticipated pain is associated with increased perceived pain with IUD insertion. Black adolescent women experience greater anticipated pain with IUD insertion. This population might benefit from counseling and clinical measures to reduce this barrier to IUD use.
Le texte complet de cet article est disponible en PDF.Key Words : Intrauterine devices, Contraceptive devices, Adolescent, Pain
Plan
| C.A. Schreiber is a consultant for Exeltis Pharmaceuticals and received research funding from Bayer Pharmaceuticals, Medicines360, ContraMed, and National Institute of Child Health and Human Development. A.Y. Akers is a consultant for the Merck HPV advisory board and is a member of the Mylan Inc Women's Health Advisory Board. The remaining authors indicate no conflicts of interest. |
|
| These data were presented in part as a poster at the American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting on May 4, 2019 in Nashville, Tennessee. |
Vol 33 - N° 1
P. 27-32 - février 2020 Retour au numéro
Article précédent
- Pediatric and Adolescent Surgical Breast Clinic: Preliminary Experience
- Osher Cohen, Efrat Avinadav, Eran Sharon, Avinoam Pirogovsky, Enrique Freud
- Misconceptions and Beliefs Regarding the Use of Intrauterine Devices for Nulliparous Women Among Chinese Health Care Providers
- Ziliang Wang, Wei Yuan, Xiaowen Tu, Hong Liang, Maohua Miao, Yan Cheng, Longmei Jin, Chaohua Lou
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?